First Author: S.Lee UK
Co Author(s): A. Yousif S. Shafquat
Back to previous
To assess the safety profile and efficacy of combined BMICS with Ozurdex® implants after treatment in patients with RVO
Retrospective study at a general district hospital in Birmingham, UK.
Patients were identified retrospectively using theatre register. All patients included had significant cataract clinically and macula oedema secondary to RVO, with no history of any forms of glaucoma or OHT. Efficacy of Ozurdex® implant was assessed from changes in central macular thickness (CMT) and visual improvement from baseline using OCT at 2 weeks and 3 months.
5 eyes from 5 patients were identified. Mean follow-up duration was 5.2 months following combined BMICS and Ozurdex® implant. The mean age of our cohort of patients was 71.4. None of the patients had previous intravitreal Lucentis injections. Mean baseline VA and CMT were 41.8 letters and 417µm respectively. Following combined BMICS and Ozurdex® implant, the mean reduction in CMT was 117.65µm at 2 weeks and 68µm at 3 months. The mean visual acuity improvement was 31.8 letters at 2 weeks and 27 letters at 3 months. At 3 months follow-up 2 eyes (40%) required listing for further Ozurdex® implant as the macula oedema had returned. Following the combined procedure 4 patients (80%) were within 1D of their aimed spherical equivalence using the IOL master. None of the patients required IOP lowering medications at 3 months. No cases of endophthalmitis/uveitis were reported.
With an average of 5.2 months follow-up after treatment with combined BMICS and Ozurdex® there was an improvement in CMT and improvement in the average number of letters read by the patients. No significant morbidities were noted and 80% of the patients achieved 1D of their aimed refractive outcome using the IOL master. Combined BMICS and intravitral Ozurdex® implant is an effective and safe option for patients who present with significant cataract and CMO secondary to retinal vein occlusion.